33.65
1.00 (3.05%)
| Penutupan Terdahulu | 32.65 |
| Jumlah Dagangan | 1,468,915 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.76 |
| Harga / Jualan (P/S) | 4.90 |
| Harga / Buku (P/B) | 3.35 |
| Julat 52 Minggu |
| Margin Keuntungan | 35.27% |
| Margin Operasi (TTM) | 26.29% |
| EPS Cair (TTM) | 1.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 1.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.70% |
| Nisbah Semasa (MRQ) | 5.34 |
| Aliran Tunai Operasi (OCF TTM) | 1.19 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.01 B |
| Pulangan Atas Aset (ROA TTM) | 11.54% |
| Pulangan Atas Ekuiti (ROE TTM) | 22.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Genmab A/S | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.75 |
|
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Growth |
| % Dimiliki oleh Institusi | 10.31% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |